Orakl Oncology

Orakl Oncology: AIxBio engine using patient-derived tumor organoids and clinical data to advance oncology drug development. BioTech · Seed · Villejuif,…

AIxBio engine using patient-derived tumor organoids and clinical data to advance oncology drug development.

Preliminary profile · public data only

Startup24 listed Orakl Oncology from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.

At a glance

Startup24 rating: 69/100

Orakl Oncology is a seed-stage oncology platform with defined products, a plausible B2B market, and a potentially valuable patient-linked organoid and clinical-data asset.

About the rating

Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.

Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.